| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 0.92% |
| NAV | ₹15.05 (24 Sep 2020) |
|---|---|
| Fund Started | 10 Jul 2019 |
| Fund Size | ₹364 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 9.8% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.8% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 8.4% |
| Cipla Ltd. | Healthcare | Equity | 8.2% |
| Lupin Ltd. | Healthcare | Equity | 5.7% |
| Metropolis Healthcare Ltd. | Healthcare | Equity | 5.0% |
| Atul Ltd. | Chemicals | Equity | 4.3% |
| Zydus Wellness Ltd. | FMCG | Equity | 4.1% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 3.7% |
| Cadila Healthcare Ltd. | Healthcare | Equity | 3.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Aditya Birla Sun Life Mutual Fund. This scheme was made available to investors on 10 Jul 2019. Dhaval Shah is the Current Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹364 Cr and the Latest NAV as of 24 Sep 2020 is ₹15.05.
The Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 1000. Exit load of 0.5% if redeemed within 90 days.
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.